Form 4: Solid Biosciences Director Ian F. Smith Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Director Ian F. Smith reports acquisition of Solid Biosciences common stock through vesting of restricted stock units.

Summary

  • On April 6, 2025, Ian F. Smith, a director of Solid Biosciences Inc., acquired 4,574 shares of common stock.
  • This acquisition resulted from the vesting of restricted stock units.
  • Following the transaction, Smith directly owns 117,546 shares of Solid Biosciences common stock and 13,719 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

  • The transaction has a minor impact on shareholders as it reflects insider activity related to compensation.

Key Dates

DateDescription
January 6, 2025Grant date of the restricted stock units
April 6, 2025Date of transaction: vesting of restricted stock units and acquisition of common stock
April 8, 2025Date of signature on the Form 4 filing

Keywords

Solid Biosciences, SLDB, Ian F. Smith, Director, Form 4, Stock Acquisition, Restricted Stock Units, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.